Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HIV PROTEASE INHIBITOR' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 98 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Dieleman, JP; Salahuddin, S; Hsu, YS; Burger, DM; Gyssens, IC; Sturkenboom, MCJM; Stricker, BHC; Kok, DJ
      Indinavir crystallization around the loop of Henle: Experimental evidence

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    2. Burger, DM; Hugen, PWH; Aarnoutse, RE; Dieleman, JP; Prins, JM; van der Poll, T; ten Veen, JH; Mulder, JW; Meenhorst, PL; Blok, WL; van der Meer, JTM; Reiss, P; Lange, JMA
      A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: Pharmacokinetics, safety, and efficacy

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    3. Hertweck, C; Sebek, P; Svatos, A
      A highly efficient and versatile synthesis of D- and L-erythro-sphinganine

      SYNLETT
    4. Lin, JH; Lu, AYH
      Interindividual variability in inhibition and induction of cytochrome P450enzymes

      ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
    5. Hilgeroth, A; Billich, A; Lilie, H
      Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors

      EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
    6. Leibenguth, P; Le Guellec, C; Besnier, JM; Bastides, F; Mace, M; Gaudet, ML; Autret-Leca, E; Paintaud, G
      Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection

      THERAPEUTIC DRUG MONITORING
    7. Duong, M; Buisson, M; Cottin, Y; Piroth, L; Lhuillier, I; Grappin, M; Chavanet, P; Wolff, JE; Portier, H
      Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: Report of four cases and review

      CLINICAL CARDIOLOGY
    8. Kanamoto, T; Kashiwada, Y; Kanbara, K; Gotoh, K; Yoshimori, M; Goto, T; Sano, K; Nakashima, H
      Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    9. Hansen, KB; Rabbat, P; Springfield, SA; Devine, PN; Grabowski, EJJ; Reider, PJ
      Asymmetric synthesis of cis-aminochromanol

      TETRAHEDRON LETTERS
    10. Suzuki, M; Nagasawa, C; Sugai, T
      Synthesis of enantiomers of indanoxazolidinone based on the lipase-catalyzed resolution of the corresponding N-carbamylamino derivative

      TETRAHEDRON
    11. Konda, Y; Takahashi, Y; Arima, S; Sato, N; Takeda, K; Dobashi, K; Baba, M; Harigaya, Y
      First total synthesis of Mer-N5075A and a diastereomeric mixture of alpha and beta-MAPI, new HIV-I protease inhibitors from a species of Streptomyces

      TETRAHEDRON
    12. Franzese, O; Lombardi, A; Comandini, A; Cannavo, E; Testorelli, C; Cirello, I; Bonmassar, E
      Effect of Saquinavir on proliferation and telomerase activity of human peripheral blood mononuclear cells

      LIFE SCIENCES
    13. Faux, J; Venisse, N; Olivier, JC; Bouquet, S
      Rapid high-performance liquid chromatography determination of lopinavir, anovel HIV-1 protease inhibitor, in human plasma

      CHROMATOGRAPHIA
    14. Lee, HB; Balasubramanian, S
      Solid-phase synthesis of N-alkyl-N-(beta-keto)amides and 1,2,4,5-tetrasubstituted imidazoles using a traceless cleavage strategy

      ORGANIC LETTERS
    15. Herradura, PS; Pendola, KA; Guy, RK
      Copper-mediated cross-coupling of aryl boronic acids and alkyl thiols

      ORGANIC LETTERS
    16. DIONISIO P; VALENTI M; CARAMELLO E; SCHILLACI E; LAMANNA D; AGOSTINI B; CHIAPPINI N; DATO I; MICHELONE G; DE SARACA M; BAJARDI P
      Acute renal failure during indinavir treatment : a new clinical setting during treatment of infections caused by retroviruses

      Italian journal of mineral and electrolyte metabolism
    17. Hugen, PWH; Burger, DM; ter Hofstede, HJM; Koopmans, PP; Hekster, YA
      Development of an indinavir oral liquid for children

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    18. Gerber, JG
      Using pharmacokinetics to optimize antiretroviral drug-drug interactions the treatment of human immunodeficiency virus infection

      CLINICAL INFECTIOUS DISEASES
    19. Sass, JO; Jakob-Solder, B; Heitger, A; Tzimas, G; Sarcletti, M
      Paronychia with pyrogenic granuloma in a child treated with indinavir: Theretinoid-mediated side effect theory revisited

      DERMATOLOGY
    20. Aungst, BJ; Nguyen, NH; Bulgarelli, JP; Oates-Lenz, K
      The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds

      PHARMACEUTICAL RESEARCH
    21. Panchagnula, R; Thomas, NS
      Biopharmaceutics and pharmacokinetics in drug research

      INTERNATIONAL JOURNAL OF PHARMACEUTICS
    22. Hilgeroth, A; Langner, A
      Bioanalysis of syn dimeric HIV-1 protease inhibitor N-benzyl 4-aryl-1,4-dihydropyridine H19: Metabolic and cytotoxic properties in Hep G2 cells

      ARCHIV DER PHARMAZIE
    23. Hilgeroth, A; Langner, A
      First bioanalytical evaluation of nonpeptidic cage dimeric HIV-1 protease inhibitor N-benzyl 4-aryl-1,4-dihydropyridine H17: Biotransformation and toxicity on Hep G2 cells

      ARCHIV DER PHARMAZIE
    24. Lerche-Langrand, C; Toutain, HJ
      Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology

      TOXICOLOGY
    25. Clayette, P; Jorajuria, S; Dormont, D
      Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors

      AIDS
    26. Huisman, MT; Smit, JW; Schinkel, AH
      Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors

      AIDS
    27. De Jaeghere, F; Allemann, E; Kubel, F; Galli, B; Cozens, R; Doelker, E; Gurny, R
      Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state

      JOURNAL OF CONTROLLED RELEASE
    28. Todd, S; Anderson, CG; Jolly, DJ; Craik, CS
      HIV protease as a target for retrovirus vector-mediated gene therapy

      BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY
    29. Gatti, G; Vigano, A; Sala, N; Vella, S; Bassetti, M; Bassetti, D; Principi, N
      Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    30. Davies, IW; Taylor, M; Marcoux, JF; Matty, L; Wu, J; Hughes, D; Reider, PJ
      Stereoselective hydrogen bromide-promoted hydrogenation of an alpha-hydroxyoxime

      TETRAHEDRON LETTERS
    31. Boruchoff, SE; Sturgill, MG; Grasing, KW; Seibold, JR; McCrea, J; Winchell, GA; Kusma, SE; Deutsch, PJ
      The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    32. Remmel, RP; Kawle, SP; Weller, D; Fletcher, CV
      Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma

      CLINICAL CHEMISTRY
    33. Wiltshire, HR; Wiltshire, BG; Clarke, AF; Worth, E; Prior, KJ; Tjia, JF
      Chromatographic and immunochemical approaches to the analysis of the HIV protease inhibitor saquinavir in plasma

      ANALYTICAL BIOCHEMISTRY
    34. Ro, S; Baek, SG; Lee, B; Ok, JH
      Conformational studies of irreversible HIV-1 protease inhibitors containing cis-epoxide as an amide isostere

      JOURNAL OF PEPTIDE RESEARCH
    35. Foisy, ML; Sommadossi, JP
      Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection

      JOURNAL OF CHROMATOGRAPHY B
    36. Zhao, ZY; Koeplinger, KA; Waldon, DJ
      Stereoselective hydroxylation of nonpeptidic HIV protease inhibitors by CYP2D6

      CHIRALITY
    37. Vickery, RD; Maurin, MB
      Utility of microcalorimetry in the characterization of the browning reaction

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    38. Domingo, P; Matias-Guiu, X; Pujol, RM; Francia, E; Lagarda, E; Sambeat, MA; Vazquez, G
      Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy

      AIDS
    39. Aungst, BJ
      P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs

      ADVANCED DRUG DELIVERY REVIEWS
    40. Poirier, JM; Robidou, P; Jaillon, P
      Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography

      THERAPEUTIC DRUG MONITORING
    41. Kiriyama, A; Nishiura, T; Yamaji, H; Takada, K
      Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor

      BIOPHARMACEUTICS & DRUG DISPOSITION
    42. Sturgill, MG; Seibold, JR; Boruchoff, SE; Yeh, KC; Haddix, H; Deutsch, P
      Trimethoprim/sulfamethoxazole does not affect the steady-state dispositionof indinavir

      JOURNAL OF CLINICAL PHARMACOLOGY
    43. Lin, JUN; Chiba, M; Chen, IW; Nishime, JA; deLuna, FA; Yamazaki, M; Lin, YJ
      Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450 A and P-glycoprotein induction

      DRUG METABOLISM AND DISPOSITION
    44. Murphy, RL; Sommadossi, JP; Lamson, M; Hall, DB; Myers, M; Dusek, A
      Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1

      JOURNAL OF INFECTIOUS DISEASES
    45. Kiso, Y; Matsumoto, H; Mizumoto, S; Kimura, T; Fujiwara, Y; Akaji, K
      Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic

      BIOPOLYMERS
    46. Confalone, PN; Waltermire, RE
      The process research and development of DuPont Merck's cyclic urea diols, a new class of HIV protease inhibitors

      PROCESS CHEMISTRY IN THE PHARMACEUTICAL INDUSTRY
    47. Hilts, AE; Fish, DN
      Dosage adjustment of antiretroviral agents in patients with organ dysfunction

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    48. HOEGL L; THOMAGREBER E; ROCKEN M; KORTING HC
      SHIFT FROM PERSISTENT ORAL PSEUDOMEMBRANOUS TO ERYTHEMATOUS CANDIDOSIS IN A HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-INFECTED PATIENT UPON COMBINATION TREATMENT WITH AN HIV PROTEASE INHIBITOR

      Mycoses
    49. Hoegl, L; Thoma-Greber, E; Rocken, M; Korting, HC
      HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study

      MYCOSES
    50. MARTINEZ F; MOMMEJAMARIN H; ESTEPAMAURICE L; BEAUFILS H; BOCHET M; DAUDON M; DERAY G; KATLAMA C
      INDINAVIR CRYSTAL DEPOSITS ASSOCIATED WITH TUBULOINTERSTITIAL NEPHROPATHY

      Nephrology, dialysis, transplantation
    51. STRICKER RB; GOLDBERG B
      WEIGHT-GAIN ASSOCIATED WITH PROTEASE INHIBITOR THERAPY IN HIV-INFECTED PATIENTS

      Research in virology
    52. ZHONG WZ; WILLIAMS MG; BORIN MT; PADBURY GE
      SPECIES-DEPENDENT ENANTIOSELECTIVE PHARMACOKINETICS OF PNU-103017, A PYRONE HIV PROTEASE INHIBITOR

      Chirality
    53. LEE CY; YANG PK; TZOU WS; HWANG MJ
      ESTIMATES OF RELATIVE BINDING FREE-ENERGIES FOR HIV PROTEASE INHIBITORS USING DIFFERENT LEVELS OF APPROXIMATIONS

      Protein engineering (Print)
    54. LABETOULLE M; GOUJARD C; FRAU E; ROGIER H; NIESSEN F; RUDENT A; LANTZ O; LECOINTE D; FURLAN V; DELFRAISSY JF; OFFRET H
      INCIDENCE AND EVOLUTION OF VIRAL RETINITIS IN HIV-INFECTED PATIENTS TREATED WITH HIV-PROTEASE INHIBITORS

      Journal francais d'ophtalmologie
    55. Lin, JH
      Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics

      DRUG METABOLISM AND DISPOSITION
    56. YEH KC; DEUTSCH PJ; HADDIX H; HESNEY M; HOAGLAND V; JU WD; JUSTICE SJ; OSBORNE B; STERRETT AT; STONE JA; WOOLF E; WALDMAN S
      SINGLE-DOSE PHARMACOKINETICS OF INDINAVIR AND THE EFFECT OF FOOD

      Antimicrobial agents and chemotherapy
    57. SHIBATA N; ITOH E; TERASHIMA S
      PRACTICAL SYNTHESIS OF (2S,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYRIC ACID, A KEY COMPONENT OF HIV PROTEASE INHIBITORS

      Chemical and Pharmaceutical Bulletin
    58. SENANAYAKE CH
      APPLICATIONS OF CIS-1-AMINO-2-INDANOL IN ASYMMETRIC-SYNTHESIS

      Aldrichimica acta
    59. JEONG YN; SEO MK; CHOI YJ; KIM IC; LEE YH
      HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF A NEW HIV-1 PROTEASEINHIBITOR, LB71350, IN THE PLASMA OF DOGS

      Journal of chromatography B. Biomedical sciences and applications
    60. FISCHL MA; RICHMAN DD; FLEXNER C; PARA MF; HAUBRICH R; KARIM A; YERAMIAN P; HOLDENWILTSE J; MEEHAN PM
      PHASE I II STUDY OF THE TOXICITY, PHARMACOKINETICS, AND ACTIVITY OF THE HIV PROTEASE INHIBITOR SC-52151/

      Journal of acquired immune deficiency syndromes and human retrovirology
    61. TAYLOR DL; AHMED PS; BRENNAN TM; BRIDGES CG; TYMS AS; VANDORSSELAER V; TARNUS C; HORNSPERGER JM; SCHIRLIN D
      ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS ACTIVITY, BIOAVAILABILITY AND DRUG-RESISTANCE PROFILE OF THE NOVEL PROTEINASE-INHIBITOR MDL-74,695

      Antiviral chemistry & chemotherapy
    62. LAZDINS JK; WALKER MR; COZENS RM; FLESCH G; CZENDLIK C; HOWALD H; KREMERS W; ALTERI E
      EX-VIVO ANTI-HIV ACTIVITY OF HUMAN SERUM OBTAINED FROM NORMAL VOLUNTEERS FOLLOWING ORAL-ADMINISTRATION OF THE HIV-1 PROTEASE INHIBITOR CGP-53437 - VALUE AS PREDICTOR OF ANTIVIRAL EFFICACY

      Antiviral chemistry & chemotherapy
    63. KOMAI T; YAGI R; SUZUKISUNAGAWA H; SAKURAI M; HIGASHIDA S; SUGANO M; HANDA H; MOHRI H; YASUOKA A; OKA S; YABE Y; NISHIGAKI T; KIMURA S; SHIMADA K
      IN-VITRO AND EX-VIVO ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ACTIVITIES OF A NEW WATER-SOLUBLE HIV PROTEASE INHIBITOR, R-87366, CONTAINING (2S,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTANOIC ACID

      Biological & pharmaceutical bulletin
    64. ROSTON DA; SUN JJ
      SUPERCRITICAL-FLUID EXTRACTION METHOD DEVELOPMENT FOR EXTRACTION OF AN EXPERIMENTAL HIV PROTEASE INHIBITOR DRUG FROM ANIMAL FEED

      Journal of pharmaceutical and biomedical analysis
    65. SHIOTANI S
      FUROPYRIDINES - SYNTHESIS AND PROPERTIES

      Heterocycles
    66. AUNGST BJ; NGUYEN NH; ROGERS NJ; ROWE SM; HUSSAIN MA; WHITE SJ; SHUM L
      AMPHIPHILIC VEHICLES IMPROVE THE ORAL BIOAVAILABILITY OF A POORLY SOLUBLE HIV PROTEASE INHIBITOR AT HIGH-DOSES

      International journal of pharmaceutics
    67. JACKSON RC
      A PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF CHEMOTHERAPY OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION THAT RELATES DEVELOPMENT OF DRUG-RESISTANCE TO TREATMENT INTENSITY

      Journal of pharmacokinetics and biopharmaceutics
    68. MASSIP P; MARCHOU B; BONNET E; CUZIN L; MONTASTRUC IL
      LIPODYSTROPHIA WITH PROTEASE INHIBITORS IN HIV PATIENTS

      Therapie
    69. WOOLF EJ; MATUSZEWSKI BK
      SIMULTANEOUS DETERMINATION OF UNLABELED AND DEUTERIUM-LABELED INDINAVIR IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH TANDEM MASS-SPECTROMETRIC DETECTION

      Journal of pharmaceutical sciences
    70. CHIBA M; HENSLEIGH M; LIN JH
      HEPATIC AND INTESTINAL METABOLISM OF INDINAVIR, AN HIV PROTEASE INHIBITOR, IN RAT AND HUMAN MICROSOMES - MAJOR ROLE OF CYP3A

      Biochemical pharmacology
    71. VONDERHELM K
      RETROVIRAL PROTEASES - STRUCTURE, FUNCTION AND INHIBITION FROM A NON-ANTICIPATED VIRAL ENZYME TO THE TARGET OF A MOST PROMISING HIV THERAPY

      Biological chemistry
    72. BECKETT RP
      RECENT ADVANCES IN THE FIELD OF MATRIX METALLOPROTEINASE INHIBITORS

      Expert opinion on therapeutic patents
    73. RAO BG; KIM EE; MURCKO MA
      CALCULATION OF SOLVATION AND BINDING FREE-ENERGY DIFFERENCES BETWEEN VX-478 AND ITS ANALOGS BY FREE-ENERGY PERTURBATION AND AMSOL METHODS

      Journal of computer-aided molecular design
    74. WALLQVIST A; COVELL DG
      DOCKING ENZYME-INHIBITOR COMPLEXES USING A PREFERENCE-BASED FREE-ENERGY SURFACE

      Proteins
    75. LEROUX JC; COZENS RM; ROESEL JL; GALLI B; DOELKER E; GURNY R
      PH-SENSITIVE NANOPARTICLES - AN EFFECTIVE MEANS TO IMPROVE THE ORAL DELIVERY OF HIV-1 PROTEASE INHIBITORS IN DOGS

      Pharmaceutical research
    76. MAURIN MB; VICKERY RD; CARNEY RF; HUSSAIN MA
      PHYSICOCHEMICAL PROPERTIES OF A NONPEPTIDE CYCLIC UREA HIV PROTEASE INHIBITOR (DMP-323)

      International journal of pharmaceutics
    77. WONG MF; HUANG PP; BRINKWORTH RI; YASHIRO M; MOHAN P; FAIRLIE D; BABA M; VERMA S
      NONPEPTIDE INHIBITORS OF HIV-1 PROTEASE - SYNTHESIS AND STRUCTURAL EVALUATION OF SYMMETRICAL AND NONSYMMETRICAL NAPHTHALENESULFONIC ACID ANALOGS

      European journal of medicinal chemistry
    78. TOBIN GJ; ENNIS WH; CLANTON DJ; GONDA MA
      INHIBITION OF BOVINE IMMUNODEFICIENCY VIRUS BY ANTI-HIV-1 COMPOUNDS IN A CELL CULTURE-BASED ASSAY

      Antiviral research
    79. KIRIYAMA A; NISHIURA T; ISHINO M; YAMAMOTO Y; OGITA I; KISO Y; TAKADA K
      BINDING CHARACTERISTICS OF KNI-272 TO PLASMA-PROTEINS, A NEW POTENT TRIPEPTIDE HIV PROTEASE INHIBITOR

      Biopharmaceutics & drug disposition
    80. KIRIYAMA A; SUGAHARA M; YOSHIKAWA Y; KISO Y; TAKADA K
      THE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF A NEW HIV-1 PROTEASE INHIBITOR, KNI-272, IN BEAGLE DOGS

      Biopharmaceutics & drug disposition
    81. TAKAHASHI M; OGASAWARA K
      LIPASE-MEDIATED RESOLUTION OF TRANS-1-AZIDOINDAN-2-OL - A NEW ROUTE TO OPTICALLY PURE CIS-1-AMINOINDAN-2-OL

      Synthesis
    82. KING BL; VAJDA S; DELISI C
      EMPIRICAL FREE-ENERGY AS A TARGET FUNCTION IN DOCKING AND DESIGN - APPLICATION TO HIV-1 PROTEASE INHIBITORS

      FEBS letters
    83. MARASTONI M; FANTIN G; BORTOLOTTI F; TOMATIS R
      SYNTHESIS AND ACTIVITY OF PSEUDOTRIPEPTIDE INHIBITORS OF HIV-1 PROTEASE CONTAINING D(-)-O-(BENZYL)TARTARIC ACID

      Arzneimittel-Forschung
    84. DEWITTE RS; SHAKHNOVICH EI
      SMOG - DE-NOVO DESIGN METHOD BASED ON SIMPLE, FAST, AND ACCURATE FREE-ENERGY ESTIMATES .1. METHODOLOGY AND SUPPORTING EVIDENCE

      Journal of the American Chemical Society
    85. KWEI GY; NOVAK LB; HETTRICK LA; REISS ER; OSTOVIC D; LOPER AE; LUI CY; HIGGINS RJ; CHEN IW; LIN JH
      REGIOSPECIFIC INTESTINAL-ABSORPTION OF THE HIV PROTEASE INHIBITOR L-735,524 IN BEAGLE DOGS

      Pharmaceutical research
    86. CHIANG CC; LONGER M; TYLE P; FESSLER D; SHETTY B
      FORMULATION DEVELOPMENT OF AN ORAL DOSAGE FORM FOR AN HIV PROTEASE INHIBITOR, AG1284

      International journal of pharmaceutics
    87. SUGAHARA M; KIRIYAMA A; HAMADA Y; KISO Y; TAKADA K
      ABSORPTION OF NEW HIV-1 PROTEASE INHIBITOR, KNI-272, AFTER INTRADUODENAL AND INTRAGASTRIC ADMINISTRATIONS TO RATS - EFFECT OF SOLVENT

      Biopharmaceutics & drug disposition
    88. PEYRAT JF; CHABOCHE C; FIGADERE B; CAVE A
      A FORMAL STEREOSELECTIVE SYNTHESIS OF A HYDROXYETHYLENE DIPEPTIDE ISOSTERE

      Tetrahedron letters
    89. ABOUABDELLAH A; BOROS L; GYENES F; WELCH JT
      NEW APPLICATIONS OF FLUORINATED BUILDING-BLOCKS

      Journal of fluorine chemistry
    90. YOSHIKAWA Y; OHTA S; TAKADA K
      A COMPUTER-PROGRAM FOR THE ANALYSIS OF CHROMATOGRAMS USED IN PHARMACOKINETIC STUDIES

      International journal of bio-medical computing
    91. KIRIYAMA A; FUJITA K; TAKEMURA S; KURAMOTO H; KISO Y; TAKADA K
      PLASMA PHARMACOKINETICS AND URINARY AND BILIARY-EXCRETION OF A NEW POTENT TRIPEPTIDE HIV-1 PROTEASE INHIBITOR, KNI-272, IN RATS AFTER INTRAVENOUS ADMINISTRATION

      Biopharmaceutics & drug disposition
    92. CIAPETTI P; TADDEI M; ULIVI P
      CRCL2 MEDIATED ALLYLATION OF N-PROTECTED ALPHA-AMINO ALDEHYDES - A VERSATILE SYNTHESIS OF POLYPEPTIDES CONTAINING AN HYDROXYETHYLENE ISOSTERE

      Tetrahedron letters
    93. SAKURAI M; HIGASHIDA S; SUGANO M; HANDA H; KOMAI T; YAGI R; NISHIGAKI T; YABE Y
      STUDIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) PROTEASE INHIBITORS .3. STRUCTURE-ACTIVITY RELATIONSHIP OF HIV-1 PROTEASE INHIBITORSCONTAINING CYCLOHEXYLALANYLALANINE HYDROXYETHYLENE DIPEPTIDE ISOSTERE

      Chemical and Pharmaceutical Bulletin
    94. KITAZAKI T; ASANO T; KATO K; KISHIMOTO S; ITOHO K
      SYNTHESIS AND HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-1 PROTEASE INHIBITORY ACTIVITY OF TRIPEPTIDE ANALOGS CONTAINING A DIOXOETHYLENE MOIETY

      Chemical and Pharmaceutical Bulletin
    95. KATO R; TAKAHASHI O; KISO Y; MORIGUCHI I; HIRONO S
      SOLUTION STRUCTURE OF HIV-1 PROTEASE-ALLOPHENYLNORSTATINE DERIVATIVE INHIBITOR COMPLEX OBTAINED FROM MOLECULAR-DYNAMICS SIMULATION

      Chemical and Pharmaceutical Bulletin
    96. KIRIYAMA A; MIMOTO T; KISANUKI S; KISO Y; TAKADA K
      COMPARISON OF A NEW ORALLY POTENT TRIPEPTIDE HIV-1 PROTEASE INHIBITOR(ANTI-AIDS DRUG) BASED ON PHARMACOKINETIC CHARACTERISTICS IN RATS AFTER INTRAVENOUS AND INTRADUODENAL ADMINISTRATIONS

      Biopharmaceutics & drug disposition
    97. SAKURAI M; SUGANO M; HANDA H; KOMAI T; YAGI R; NISHIGAKI T; YABE Y
      STUDIES OF HIV-1 PROTEASE INHIBITORS .1. INCORPORATION OF A REDUCED PEPTIDE, SIMPLE AMINOALCOHOL, AND STATINE ANALOG AT THE SCISSILE SITE OF SUBSTRATE SEQUENCES

      Chemical and Pharmaceutical Bulletin
    98. SAKURAI M; HIGASHIDA S; SUGANO M; NISHI T; SAITO F; OHATA Y; HANDA H; KOMAI T; YAGI R; NISHIGAKI T; YABE Y
      STUDIES OF HIV-1 PROTEASE INHIBITORS .2. INCORPORATION OF 4 TYPES OF HYDROXYETHYLENE DIPEPTIDE ISOSTERES AT THE SCISSILE SITE OF SUBSTRATE SEQUENCES

      Chemical and Pharmaceutical Bulletin


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/05/20 alle ore 23:50:30